<DOC>
	<DOC>NCT00103857</DOC>
	<brief_summary>The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with Type 2 Diabetes Mellitus (T2DM) (a specific type of diabetes).</brief_summary>
	<brief_title>MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>54Week Base Study: Patients between the ages of 18 and 78 with Type 2 Diabetes Mellitus (a specific type of diabetes) 50Week Extension Study: Patients who complete the 54week base study are eligible to enter the 50week extension study Patients who do not have Type 2 Diabetes Mellitus (a specific type of diabetes)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>